The study features in-depth analyses, highlighting the capabilities of a diverse set of biopharmaceu
To order this detailed 780+ page report, please visit this link
A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring an elaborate list of active CMOs, along with information on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), scale of operation (preclinical, clinical and commercial), types of expression systems used (mammalian, microbial and others), type of bioreactor used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion), bioprocessing capacity and type of packaging.
A detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), and including an analysis based on the location of these facilities, highlighting key manufacturing hubs for biologics.
Elaborate profiles of key players that claim to have a diverse range of capabilities related to the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as an informed future outlook.
A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.